Patricia D. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patricia D. Jones has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
- Paulo S. Pinheiro
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA
19 shared publications - Robert John Wong
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA
19 shared publications - Amit G. Singal
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
14 shared publications - Mandana Khalili
University of California, San Francisco
13 shared publications Paul Martin
Department of Medicine, Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida
12 shared publications- Anna Thiemann
Department of Medicine, California Pacific Medical Center, San Francisco, California
10 shared publications
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Baseline Characteristics of a Prospective, Multicenter Study on the Natural History of Compensated Cirrhosis: The Liver Cirrhosis Network
In 2021, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Cancer Institute (NCI) sponsored the multicenter Liver Cirrhosis Network (LCN) Cohort Study (NCT05740358) to prospectively enroll individuals with compensated cirrhosis to define the natural history of compensated cirrhosis and develop risk stratification tools. Here, we describe baseline demographic and clinical characteristics of the cohort and compare characteristics of participants with always compensated versus recompensated cirrhosis. We found that LCN Cohort Study participants have similar demographics to the broader cirrhosis population in the United States, making the network's stated aims of determining risk factors for hepatic decompensation generalizable to clinical practice in the United States.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Baseline Characteristics of a Prospective, Multicenter Study on the Natural History of Compensated Cirrhosis: The Liver Cirrhosis Network
In 2021, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Cancer Institute (NCI) sponsored the multicenter Liver Cirrhosis Network (LCN) Cohort Study (NCT05740358) to prospectively enroll individuals with compensated cirrhosis to define the natural history of compensated cirrhosis and develop risk stratification tools. Here, we describe baseline demographic and clinical characteristics of the cohort and compare characteristics of participants with always compensated versus recompensated cirrhosis. We found that LCN Cohort Study participants have similar demographics to the broader cirrhosis population in the United States, making the network's stated aims of determining risk factors for hepatic decompensation generalizable to clinical practice in the United States.
- Open Access
- 29 July 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (11)
Metabolic Dysfunction–Associated Steatotic Liver Disease Is Associated With Adverse Social Factors: An Analysis Using All of Us
- 29 July 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (11)
Open AccessMetabolic Dysfunction–Associated Steatotic Liver Disease Is Associated With Adverse Social Factors: An Analysis Using All of Us
- Open Access
- 29 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Financial burden among liver transplant candidates is associated with financial distress and work impairment: A U.S. multicenter study
Background: The financial impact of chronic liver disease among adults undergoing liver transplant (LT) evaluation remains understudied. We performed a cross-sectional multicenter study to explore high financial burden, defined as medical out-of-pocket expenses ≥10% of income (per prior literature), among adult LT candidates. We aimed to identify associations between high financial burden and (1) work productivity impairment; (2) financial distress (material, behavioral, and psychological consequences of financial burden); (3) financial toxicity (health-related quality of life, HRQOL). Methods: From May 2023 to April 2024, 453 patients from 13 United States transplant centers were included. Patients completed questionnaires assessing financial burden, financial distress, financial toxicity (EuroQol EQ-5D-5L instrument), and work productivity and impairment (Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Version). Results: Among LT candidates, 23.3% reported a high financial burden, and only 27.6% were employed. High financial burden was associated with a higher rate of absenteeism from work (34.1% vs. 16.9%, p =0.018) among employed participants. In adjusted models, high financial burden was significantly associated with inability to pay for basic necessities (aOR 4.76, 95% CI: 2.34–9.67), delayed or foregone medical care (aOR 4.02, 95% CI: 2.30–7.02), and psychological distress (aOR 4.63, 95% CI: 1.95–10.98) but was not associated with HRQOL (EQ-5D β: −0.04, 95% CI: −0.08 to 0.00; EQ-5D-VAS β: −4.53, 95% CI: −10.1 to 1.02). Conclusion: These results highlight the critical importance of implementing routine screening for financial burden in this high-risk population and developing strategies to mitigate associated adverse outcomes.
- 29 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Open AccessFinancial burden among liver transplant candidates is associated with financial distress and work impairment: A U.S. multicenter study
Background: The financial impact of chronic liver disease among adults undergoing liver transplant (LT) evaluation remains understudied. We performed a cross-sectional multicenter study to explore high financial burden, defined as medical out-of-pocket expenses ≥10% of income (per prior literature), among adult LT candidates. We aimed to identify associations between high financial burden and (1) work productivity impairment; (2) financial distress (material, behavioral, and psychological consequences of financial burden); (3) financial toxicity (health-related quality of life, HRQOL). Methods: From May 2023 to April 2024, 453 patients from 13 United States transplant centers were included. Patients completed questionnaires assessing financial burden, financial distress, financial toxicity (EuroQol EQ-5D-5L instrument), and work productivity and impairment (Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Version). Results: Among LT candidates, 23.3% reported a high financial burden, and only 27.6% were employed. High financial burden was associated with a higher rate of absenteeism from work (34.1% vs. 16.9%, p =0.018) among employed participants. In adjusted models, high financial burden was significantly associated with inability to pay for basic necessities (aOR 4.76, 95% CI: 2.34–9.67), delayed or foregone medical care (aOR 4.02, 95% CI: 2.30–7.02), and psychological distress (aOR 4.63, 95% CI: 1.95–10.98) but was not associated with HRQOL (EQ-5D β: −0.04, 95% CI: −0.08 to 0.00; EQ-5D-VAS β: −4.53, 95% CI: −10.1 to 1.02). Conclusion: These results highlight the critical importance of implementing routine screening for financial burden in this high-risk population and developing strategies to mitigate associated adverse outcomes.
- Open Access
A Paracrine Dietary Lipid Axis Constrains Antitumor Immunity in Liver Cancer
Overnutrition-related liver dysfunction and cancer are increasingly prevalent and highly resistant to immunotherapy. While metabolic dysregulation is a hallmark of hepatocellular carcinoma (HCC), how nutrient overload impairs antitumor immunity remains unclear. Here, we show that short-term Western diet (WD) exposure drives near-complete loss of CD8⁺ T cell infiltration and antitumor function in HCC. We identify dietary linoleic acid (LA), the most abundant ω-6 fatty acid, as the dominant immunosuppressive driver. Cancer cell-restricted FADS2-mediated desaturation of LA to longer-chain ω-6 PUFAs drives their accumulation in the tumor interstitial fluid, suppressing infiltrating CD8⁺ T cells via lipid peroxidation. FADS2 inhibition restores CD8⁺ T cell function and sensitizes WD-driven HCC to PD-1-based immunotherapy. Further, the Parkinson's disease-associated deglycase DJ-1 protects LA-handling proteins from methylglyoxal-mediated glycation, sustaining tumoral immunosuppressive PUFA production. Across multiple independent human MASLD-HCC cohorts, LA metabolic activity correlates with CD8⁺ T cell impairment, immune exclusion, and immunotherapy resistance. Overall, these studies identify a dietary lipid axis as a therapeutically actionable vulnerability in WD-associated HCC.
Open AccessA Paracrine Dietary Lipid Axis Constrains Antitumor Immunity in Liver Cancer
Overnutrition-related liver dysfunction and cancer are increasingly prevalent and highly resistant to immunotherapy. While metabolic dysregulation is a hallmark of hepatocellular carcinoma (HCC), how nutrient overload impairs antitumor immunity remains unclear. Here, we show that short-term Western diet (WD) exposure drives near-complete loss of CD8⁺ T cell infiltration and antitumor function in HCC. We identify dietary linoleic acid (LA), the most abundant ω-6 fatty acid, as the dominant immunosuppressive driver. Cancer cell-restricted FADS2-mediated desaturation of LA to longer-chain ω-6 PUFAs drives their accumulation in the tumor interstitial fluid, suppressing infiltrating CD8⁺ T cells via lipid peroxidation. FADS2 inhibition restores CD8⁺ T cell function and sensitizes WD-driven HCC to PD-1-based immunotherapy. Further, the Parkinson's disease-associated deglycase DJ-1 protects LA-handling proteins from methylglyoxal-mediated glycation, sustaining tumoral immunosuppressive PUFA production. Across multiple independent human MASLD-HCC cohorts, LA metabolic activity correlates with CD8⁺ T cell impairment, immune exclusion, and immunotherapy resistance. Overall, these studies identify a dietary lipid axis as a therapeutically actionable vulnerability in WD-associated HCC.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 3. Assessment of the proportional-hazards assumption using Schoenfeld residuals
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 3. Assessment of the proportional-hazards assumption using Schoenfeld residuals
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Background:Aflatoxin remains an underrecognized hepatocellular carcinoma (HCC) risk factor in the United States, where the permissible food limit (20 ppb) is fivefold higher than in Europe.Methods:We analyzed 350 The Cancer Genome Atlas HCC cases with whole-exome sequencing, RNA sequencing, and clinical data. Aflatoxin burden was quantified by single-base substitution signature 24. HLA diversity was quantified from RNA sequencing reads using the Shannon diversity index. Multivariable Cox models estimated HRs for disease-specific survival (DSS) with aflatoxin–virus interactions, adjusting for tumor stage, age, sex, race, alcohol use, fatty liver disease, aristolochic acid signature, and HLA diversity. Linear regression evaluated the association between HLA diversity and aflatoxin burden.Results:Higher aflatoxin burden was associated with poorer DSS (adjusted HR = 1.16; 95% confidence interval, 1.01–1.33). Among hepatitis C virus (HCV)-positive patients, hepatitis B virus (HBV) infection was associated with improved DSS at low aflatoxin levels; however, this association was reversed at aflatoxin levels exceeding 30 units. HCV infection was consistently associated with worse DSS across aflatoxin levels. Asian American and Black/African American patients carried higher aflatoxin burdens than Whites (P = 0.016 and 0.014). Greater HLA diversity was independently associated with lower aflatoxin burden (P < 0.001), suggesting a protective effect.Conclusions:Somatic aflatoxin exposure, both independently and synergistically with HBV/HCV infection, adversely affects HCC prognosis, whereas greater HLA diversity may mitigate the detrimental effects of aflatoxin. Aflatoxin exposure disproportionately affected Asian American and Black/African American patients (other minority groups not represented).Impact:Tightening US aflatoxin food limits and expanding HBV vaccination coverage in high-risk communities could reduce HCC disparities and improve patient survival.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Background:Aflatoxin remains an underrecognized hepatocellular carcinoma (HCC) risk factor in the United States, where the permissible food limit (20 ppb) is fivefold higher than in Europe.Methods:We analyzed 350 The Cancer Genome Atlas HCC cases with whole-exome sequencing, RNA sequencing, and clinical data. Aflatoxin burden was quantified by single-base substitution signature 24. HLA diversity was quantified from RNA sequencing reads using the Shannon diversity index. Multivariable Cox models estimated HRs for disease-specific survival (DSS) with aflatoxin–virus interactions, adjusting for tumor stage, age, sex, race, alcohol use, fatty liver disease, aristolochic acid signature, and HLA diversity. Linear regression evaluated the association between HLA diversity and aflatoxin burden.Results:Higher aflatoxin burden was associated with poorer DSS (adjusted HR = 1.16; 95% confidence interval, 1.01–1.33). Among hepatitis C virus (HCV)-positive patients, hepatitis B virus (HBV) infection was associated with improved DSS at low aflatoxin levels; however, this association was reversed at aflatoxin levels exceeding 30 units. HCV infection was consistently associated with worse DSS across aflatoxin levels. Asian American and Black/African American patients carried higher aflatoxin burdens than Whites (P = 0.016 and 0.014). Greater HLA diversity was independently associated with lower aflatoxin burden (P < 0.001), suggesting a protective effect.Conclusions:Somatic aflatoxin exposure, both independently and synergistically with HBV/HCV infection, adversely affects HCC prognosis, whereas greater HLA diversity may mitigate the detrimental effects of aflatoxin. Aflatoxin exposure disproportionately affected Asian American and Black/African American patients (other minority groups not represented).Impact:Tightening US aflatoxin food limits and expanding HBV vaccination coverage in high-risk communities could reduce HCC disparities and improve patient survival.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Table 1. Univariable Cox regression results for DSS.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Table 1. Univariable Cox regression results for DSS.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 1. Forest plot of multivariable Cox regression model for DSS.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 1. Forest plot of multivariable Cox regression model for DSS.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 2. Forest plot of stratified analysis for DSS.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Aflatoxin Exposure, Chronic Hepatitis Infection, and HLA Diversity Converge to Shape Patient Survival in Hepatocellular Carcinoma
Supplementary Figure 2. Forest plot of stratified analysis for DSS.
- Open Access
- 17 March 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 69
Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a leading cause of cancer-related death. There are significant disparities in risk, receipt of screening for HCC, stage at diagnosis, receipt of treatment and survival. Differential HCC risk for HCC is driven by variation in the etiology of underlying liver disease, which varies by race, ethnicity, gender, and geographic location. Sociocultural and structural forces influence access to health care, which may limit adherence to guideline-recommended HCC screening intervals. Black race and uninsured status are associated with decreased likelihood of receiving HCC screening. These disparities in screening impact stage at presentation as patients who are diagnosed through screening present at earlier stages of disease compared to patients who are diagnosed due to symptoms. Socioeconomic status, geography, race, and ethnicity are all associated with receipt of treatment and survival after HCC diagnosis. Guided by the National Institute on Minority Health and Health Disparities (NIMHD) Research Framework, this work aims to present a comprehensive overview of disparities in HCC risk, screening, diagnosis, treatment, and outcomes.
- 17 March 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 69
Open AccessDisparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a leading cause of cancer-related death. There are significant disparities in risk, receipt of screening for HCC, stage at diagnosis, receipt of treatment and survival. Differential HCC risk for HCC is driven by variation in the etiology of underlying liver disease, which varies by race, ethnicity, gender, and geographic location. Sociocultural and structural forces influence access to health care, which may limit adherence to guideline-recommended HCC screening intervals. Black race and uninsured status are associated with decreased likelihood of receiving HCC screening. These disparities in screening impact stage at presentation as patients who are diagnosed through screening present at earlier stages of disease compared to patients who are diagnosed due to symptoms. Socioeconomic status, geography, race, and ethnicity are all associated with receipt of treatment and survival after HCC diagnosis. Guided by the National Institute on Minority Health and Health Disparities (NIMHD) Research Framework, this work aims to present a comprehensive overview of disparities in HCC risk, screening, diagnosis, treatment, and outcomes.